DocWire News Editors

DocwireNews

At the annual meeting, researchers led by Xenofon Baraliakos, MD, of the Ruhr-University of Bochum in Germany, presented long-term, end-of-study findings from the phase III MEASURE 1 extension trial, which is evaluating the safety and efficacy of secukinumab (SEC) in patients with ankylosing spondylitis (AS). The researchers examined signs and symptoms, physical function, and objective markers of inflammation through five years. They found sustained efficacy, which improved with dose escalation, and the treatment was well tolerated.SEC is a fully human monoclonal IgG1 antibody that selectively neutralizes interleukin-17A. It is the only biologic disease-modifying anti-rheumatic drug approved by the U.S. Food and Drug Administration for use in AS, other than tumor necrosis factor inhibitors.In the MEASURE 1 study, researchers initially randomized patients to receive placebo or intravenous SEC 10 mg/kg at baseline and at weeks two and four, followed by subcutaneous SEC 150 mg or 75 mg every four weeks thereafter. Then, based on Assessment in Ankylosing Spondylitis (ASAS) Response Criteria at week 16, the researchers took patients re-randomized those taking placebo to receive SEC 150 mg or 75 mg at week 16 (non-responders) or week 24 (responders).After the initial trial of two years, 274 patients entered the three-year extension study, which assessed outcomes at week 260. Results reported included all patients in the extension trial, including those who switched from placebo.Overall, 108 of 128 patients (84.4%) who received SEC 150 mg and 122 of 146 patients (83.6%) who received SEC 75 mg completed 260 weeks of treatment. Sustained improvements were noted in outcome assessments, including ASAS and the Bath Ankylosing Spondylitis Disease Activity Index. Eighty-two patients (56.2%) who had been receiving SEC 75 mg received dose escalation to 150 mg after week 168, and their outcome assessments improved. In addition, the researchers noted, SEC was well tolerated, and the treatment&rsquo;s safety profile was consistent over the entire study period.The study concluded that SEC provided sustained efficacy in signs and symptoms, physical function, and objective markers of inflammation for patients with AS through five years. Dose escalation from 75 mg to 150 mg provided improved efficacy. Finally, SEC was well tolerated over the long term, with a similar safety profile as previously reported.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Data Show Efficacy of Secukinumab in Multiple Aspects of Ankylosing Spondylitis After 5 Years

ACR 2018 Conference

At the annual meeting, researchers led by Xenofon Baraliakos, MD, of the Ruhr-University of Bochum in Germany, presented long-term, end-of-study findings from the phase III ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe